πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8211876

Compositions for treatment of inflammatory diseases

The Regents of the University of Oklahoma Β· Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8211857

Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

Soricimed Biopharma Inc. Β· Granted Tue Jul 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 28 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8193152

Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

The Board of Regents of the University of Texas System Β· Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8192720

Compositions and methods for detection, prevention, and treatment of anthrax and other inf

BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE OF THE UNIVERSITY OF NEVADA, RENO Β· Granted Tue Jun 05 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 31 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8188072

Benzodiazepinone compounds useful in the treatment of skin conditions

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8187817

Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies

XBIOTECH INC. Β· Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8183274

Treatment of hyperproliferative disorders with diarylhydantoin compounds

The Regents of the University of California Β· Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8183207

Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molec

Five Prime Therapeutics, Inc. Β· Granted Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8178109

Compositions and methods of use for MGD-CSF in disease treatment

Five Prime Therapeutics, Inc. Β· Granted Tue May 15 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 10 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8173120

Method of preventing reduced feed intake in animals and treatment of disease conditions

Precision Nutrition Pty Ltd Β· Granted Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8163281

Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8158677

Treatment of viral infections by modulation of host cell metabolic pathways

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8158675

Compounds and methods for the treatment or prevention of Flavivirus infections

Vertex Pharmaceuticals (Canada) Incorporated Β· Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8158627

Compositions and treatments using pyridazine compounds and cholinesterase inhibitors

Northwestern University Β· Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8153604

CNS-tumor treatment method and composition

The Regents of the University of California Β· Granted Tue Apr 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8147833

Prevention and treatment of synucleinopathic and amyloidogenic disease

The Regents of the University of California Β· Granted Tue Apr 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8143226

Tyrosine kinase receptor antagonists and methods of treatment for breast cancer

The Regents of the University of California Β· Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8143218

Treatment of skin, and wound repair, with thymosin beta 4

REGENERX BIOPHARMACEUTICALS, INC. Β· Granted Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8138351

Treatment of duchenne muscular dystrophy

Summit Corporation Plc Β· Granted Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8129349

Treatment of disease by inducing cell apoptosis

The Regents of the University of California Β· Granted Tue Mar 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8124653

Methods and compositions for the treatment of attention deficit hyperactivity disorder and

The Board of Regents of the University of Texas System Β· Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8119827

Compounds for treatment of cell proliferative diseases

The Board of Regents of the University of Texas System Β· Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8119649

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

The Board of Regents of the University of Texas System Β· Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8119618

Compositions and methods for the treatment of inflammatory diseases

The Board of Regents of the University of Oklahoma Β· Granted Tue Feb 21 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted